An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
Like Lilly Regeneron reports promising but not emphatic data with its antibody treatment, and the question turns to approvability.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.